LRE vs. MDC, CCT, PRIM, CCS, GEO, EME, PHM, J, MTH, and ROAD
Should you be buying Lancashire stock or one of its competitors? The main competitors of Lancashire include Mediclinic International (MDC), The Character Group (CCT), Primorus Investments (PRIM), Crossword Cybersecurity (CCS), Georgian Mining (GEO), Empyrean Energy (EME), Phimedix Plc (PHM.L) (PHM), Jacobs Engineering Group (J), Mithras Investment Trust (MTH), and Roadside Real Estate (ROAD). These companies are all part of the "construction" industry.
Lancashire vs.
Lancashire (LON:LRE) and Mediclinic International (LON:MDC) are both financial services companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, community ranking, institutional ownership, valuation, dividends and profitability.
Lancashire has a net margin of 26.72% compared to Mediclinic International's net margin of 4.99%. Lancashire's return on equity of 23.96% beat Mediclinic International's return on equity.
Lancashire has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Mediclinic International has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500.
In the previous week, Lancashire had 4 more articles in the media than Mediclinic International. MarketBeat recorded 4 mentions for Lancashire and 0 mentions for Mediclinic International. Lancashire's average media sentiment score of 0.62 beat Mediclinic International's score of 0.00 indicating that Lancashire is being referred to more favorably in the media.
Lancashire has higher earnings, but lower revenue than Mediclinic International. Mediclinic International is trading at a lower price-to-earnings ratio than Lancashire, indicating that it is currently the more affordable of the two stocks.
Lancashire received 115 more outperform votes than Mediclinic International when rated by MarketBeat users. However, 57.33% of users gave Mediclinic International an outperform vote while only 44.53% of users gave Lancashire an outperform vote.
Lancashire presently has a consensus target price of GBX 781, indicating a potential upside of 19.60%. Given Lancashire's stronger consensus rating and higher possible upside, research analysts plainly believe Lancashire is more favorable than Mediclinic International.
60.5% of Lancashire shares are held by institutional investors. Comparatively, 39.2% of Mediclinic International shares are held by institutional investors. 0.6% of Lancashire shares are held by company insiders. Comparatively, 48.9% of Mediclinic International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Lancashire pays an annual dividend of GBX 18 per share and has a dividend yield of 2.8%. Mediclinic International pays an annual dividend of GBX 3 per share. Lancashire pays out 1,592.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Mediclinic International pays out 1,304.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Summary
Lancashire beats Mediclinic International on 14 of the 19 factors compared between the two stocks.
Get Lancashire News Delivered to You Automatically
Sign up to receive the latest news and ratings for LRE and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lancashire Competitors List
Related Companies and Tools
This page (LON:LRE) was last updated on 1/21/2025 by MarketBeat.com Staff
Free LRE Stock Alerts